Sobi's Gamifant Shows Promise in Phase 2a Trial for Interferon-Gamma-Driven Sepsis
核心洞察
Sobi (搜索) announced positive topline results from the Phase 2a EMBRACE study evaluating Gamifant (emapalumab) for interferon-gamma-driven sepsis (搜索), showing proof-of-concept with improvements in organ dysfunction and survival.
The trial targeted a newly identified sepsis (搜索) endotype affecting approximately 20% of sepsis patients, characterized by elevated CXCL9 (搜索) levels and poor clinical outcomes with 28-day mortality rates of 40-43%.
Based on these encouraging results, Sobi (搜索) and the Hellenic Institute for the Study of Sepsis will advance emapalumab development and discuss next clinical steps with regulatory authorities.
Sobi (搜索) announced positive topline results from the Phase 2a EMBRACE study evaluating Gamifant (emapalumab) for interferon-gamma (IFNγ)-driven sepsis (搜索) (IDS), demonstrating proof-of-concept with observed improvements in organ dysfunction and survival. The Swedish biopharma company will advance the anti-interferon gamma monoclonal antibody into further clinical development based on data from this research collaboration with the Hellenic Institute for the Study of Sepsis (HISS).
Targeting a Newly Identified Sepsis Endotype
The EMBRACE study focused on interferon-gamma-driven sepsis (搜索), a recently described endotype that affects approximately 20% of sepsis (搜索) patients. According to a large study published in eBioMedicine in 2024, different sepsis endotypes require differentiated treatment strategies. IDS is characterized by elevated levels of CXCL9 (搜索) and detectable IFNγ, with particularly poor clinical outcomes including 28-day mortality rates ranging from 40 to 43%.
Sepsis (搜索) remains a serious condition in response to infection that can lead to organ failure and represents a leading global cause of mortality. The identification of distinct sepsis endotypes opens new avenues for precision medicine approaches in critical care.
EMBRACE Trial Design and Endpoints
The Phase 2a, double-blind, randomized controlled trial was conducted at 24 sites in Greece, enrolling a total of 75 patients. The study investigated whether Gamifant could improve clinical outcomes in patients with the IDS endotype who showed absence of sepsis (搜索)-induced immunoparalysis.
The trial employed a three-arm design comparing two different doses of Gamifant (low and high) alongside standard-of-care treatment against placebo plus standard-of-care treatment. The primary endpoint measured a ≥1.4-point decrease in the Sequential Organ Failure Assessment (SOFA) score from baseline to the end of treatment at 28 days.
Secondary endpoints included 28-day mortality, safety, pharmacokinetics, and changes in key inflammatory biomarkers such as CRP, IL-6, ferritin, IFNγ, and CXCL9 (搜索). By targeting the inflammation pathway characteristic of IDS, the trial aimed to reduce mortality, improve organ function, and accelerate patient recovery.
Gamifant's Mechanism and Current Approvals
Gamifant (emapalumab) is an anti-interferon gamma monoclonal antibody that binds to and neutralizes IFNγ. When IFNγ is secreted in an uncontrolled manner, hyperinflammation occurs within the body. The drug is administered through intravenous infusion over one hour twice per week.
In the United States, Gamifant is currently indicated for treating adult and pediatric patients with primary hemophagocytic lymphohistiocytosis (搜索) (HLH) with refractory, recurrent or progressive disease or intolerance to conventional HLH therapy. The drug is also approved for treating HLH/macrophage activation syndrome (搜索) (MAS) in known or suspected Still's disease (搜索) with inadequate response or intolerance to glucocorticoids, or with recurrent MAS.
Primary HLH is a rare syndrome of hyperinflammation that usually occurs within the first year of life and can rapidly become fatal unless diagnosed and treated.
Next Steps and Regulatory Discussions
Based on the encouraging EMBRACE study results, Sobi (搜索) and HISS will advance emapalumab development in IDS and initiate discussions with regulatory authorities regarding next clinical development steps. The companies plan to provide updates on the development pathway in due course, and data from the EMBRACE study will be presented at an upcoming medical conference.
The collaboration with HISS, a non-profit academic institute focused on precision immunotherapy, represents part of the organization's broader research portfolio. Since 2010, HISS has published 125 peer-reviewed publications, organized 15 conferences, and conducted 35 clinical studies, with data published in journals including Nature Medicine and JAMA.